Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to neworal anticoagulants

JAMA Neurology

Volumn 73, Issue 2, 2016, Pages 169-177

  Purrucker, Jan C ^a   Haas, Kirsten ^b   Rizos, Timolaos ^a   Khan, Shujah ^a   Wolf, Marcel ^a   Hennerici, Michael G ^c   Poli, Sven ^d   Kleinschnitz, Christoph ^b   Steiner, Thorsten ^a,e   Heuschmann, Peter U ^b   Veltkamp, Roland ^a,f  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e SANOFI   (France)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; NONVITAMIN K ANTAGONIST ORAL ANTICOAGULANT AGENT; PROTHROMBIN COMPLEX; RIVAROXABAN; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR; PROTHROMBIN COMPLEX CONCENTRATES;

ADULT; AGED; ARTICLE; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN RADIOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RANKIN SCALE; VERY ELDERLY; ADOLESCENT; BLOOD PRESSURE; CEREBRAL HEMORRHAGE; CLINICAL TRIAL; DRUG EFFECTS; HEMATOMA; MIDDLE AGED; MULTICENTER STUDY; ODDS RATIO; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; RADIOGRAPHY; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; BLOOD PRESSURE; CEREBRAL HEMORRHAGE; FEMALE; HEMATOMA; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84964788312     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.3682     Document Type: Article

References (55)

1. Fang MC, Go AS, Chang Y, et al. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke. 2012;43(7):1795-1799.
2. Held C, Hylek EM, Alexander JH, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J. 2015;36(20):1264-1272.
3. Davis SM, Broderick J, Hennerici M, et al; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006; 66(8):1175-1181.
4. Horstmann S, Rizos T, Lauseker M, et al. Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: a consecutive observational study. J Neurol. 2013;260(8):2046-2051.
5. Béjot Y, Cordonnier C, Durier J, Aboa-Eboulé C, Rouaud O, Giroud M. Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study. Brain. 2013;136(pt 2):658-664.
6. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63(6):1059-1064.
7. Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313(8):824-836.
8. Hanger HC, Fletcher VJ, Wilkinson TJ, Brown AJ, Frampton CM, Sainsbury R. Effect of aspirin and warfarin on early survival after intracerebral haemorrhage. J Neurol. 2008;255(3):347-352.
9. Dogliotti A, Paolasso E, Giugliano RP. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin. Clin Cardiol. 2013;36(2):61-67.
10. Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol. 2013;70(12):1486-1490.
11. Luger S, Hohmann C, Kraft P, et al. Prescription frequency and predictors for the use of novel direct oral anticoagulants for secondary stroke prevention in the first year after their marketing in Europe: a multicentric evaluation. Int J Stroke. 2014;9(5): 569-575.
12. Hankey GJ, Stevens SR, Piccini JP, et al; ROCKET AF Steering Committee and Investigators. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation. Stroke. 2014;45 (5):1304-1312.
13. Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012;43(6):1511-1517.
14. Simonsen CZ, Steiner T, Tietze A, Damgaard D. Dabigatran-related intracerebral hemorrhage resulting in hematoma expansion. J Stroke Cerebrovasc Dis. 2014;23(2):e133-e134. doi:10.1016/j.jstrokecerebrovasdis.2013.08.011.
15. Purrucker JC, Capper D, Behrens L, Veltkamp R. Secondary hematoma expansion in intracerebral hemorrhage during rivaroxaban therapy. Am J Emerg Med. 2014;32(8):947.e3-947.e5. doi:10.1016/j.ajem.2014.01.042.
16. Faust AC, Peterson EJ. Management of dabigatran-associated intracerebral and intraventricular hemorrhage: a case report. J Emerg Med. 2014;46(4):525-529.
17. Ross B, Miller MA, Ditch K, Tran M. Clinical experience of life-threatening dabigatran-related bleeding at a large, tertiary care, academic medical center: a case series. J Med Toxicol. 2014;10(2):223-228.
18. Kasliwal MK, Panos NG, Munoz LF, Moftakhar R, Lopes DK, Byrne RW. Outcome following intracranial hemorrhage associated with novel oral anticoagulants. J Clin Neurosci. 2015;22(1):212-215.
19. Komori M, Yasaka M, Kokuba K, et al. Intracranial hemorrhage during dabigatran treatment. Circ J. 2014;78(6):1335-1341.
20. Stöllberger C, Zuntner G, Bastovansky A, Finsterer J. Cerebral hemorrhage under rivaroxaban. Int J Cardiol. 2013;167(6):e179-e181. doi:10.1016/j.ijcard.2013.03.185.
21. Aslan O, Yaylali YT, Yildirim S, et al. Dabigatran versus warfarin in atrial fibrillation: multicenter experience in Turkey [published online August 12, 2014]. Clin Appl Thromb Hemost.
22. Saji N, Kimura K, Aoki J, Uemura J, Sakamoto Y. Intracranial hemorrhage caused by non-vitamin K antagonist oral anticoagulants (NOACs): multicenter retrospective cohort study in Japan [published correction appears in Circ J. 2015;79(6):1393-1395]. Circ J. 2015;79(5):1018-1023.
23. Beynon C, Sakowitz OW, Störzinger D, et al. Intracranial haemorrhage in patients treated with direct oral anticoagulants. Thromb Res. 2015;136(3): 560-565.
24. Akiyama H, Uchino K, Hasegawa Y. Characteristics of symptomatic intracranial hemorrhage in patients receiving non-vitamin K antagonist oral anticoagulant therapy. PLoS One. 2015;10(7):e0132900. doi:10.1371/journal.pone.0132900.
25. Morgenstern LB, Hemphill JC III, Anderson C, et al; American Heart Association Stroke Council and Council on Cardiovascular Nursing. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41(9):2108-2129.
26. Masotti L, Di Napoli M, Godoy DA, et al. The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy. Int J Stroke. 2011;6(3):228-240.
27. Steiner T, Al-Shahi Salman R, Beer R, et al; European Stroke Organisation. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke. 2014;9(7):840-855.
28. Parry-Jones AR, Di Napoli M, Goldstein JN, et al. Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage. Ann Neurol. 2015; 78(1):54-62.
29. Steiner T, Böhm M, Dichgans M, et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol. 2013;102(6):399-412.
30. Heidbuchel H, Verhamme P, Alings M, et al; European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5): 625-651.
31. Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014;63(20):2141-2147.
32. Gomez-Outes A, Suarez-Gea ML, Lecumberri R, Terleira-Fernandez AI, Vargas-Castrillon E. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9(1):2-10.
33. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511-520.
34. Zhou W, Zorn M, Nawroth P, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke. 2013;44(3):771-778.
35. Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42(12):3594-3599.
36. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573-1579.
37. Levi M, Moore KT, Castillejos CF, et al. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost. 2014;12 (9):1428-1436.
38. Lip GY, Lane DA, Buller H, Apostolakis S. Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS study. Chest. 2013;144(6):1839-1847.
39. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57(2):173-180.
40. Hinson HE, Hanley DF, Ziai WC. Management of intraventricular hemorrhage. Curr Neurol Neurosci Rep. 2010;10(2):73-82.
41. Heinze G, Ploner M. Fixing the nonconvergence bug in logistic regression with SPLUS and SAS. Comput Methods Programs Biomed. 2003;71(2):181-187.
42. Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med. 2002;21(16):2409-2419.
43. Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80(1):27-38.
44. Mayer SA, Brun NC, Begtrup K, et al; FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358(20):2127-2137.
45. Flaherty ML, Tao H, Haverbusch M, et al. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008;71(14):1084-1089.
46. Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Hillbom M. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke. 2011; 42(9):2431-2435.
47. Flaherty ML. Anticoagulant-associated intracerebral hemorrhage. Semin Neurol. 2010;30 (5):565-572.
48. Hagii J, Tomita H, Metoki N, et al. Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin. Stroke. 2014;45(9):2805-2807.
49. Pezzini A, Grassi M, Paciaroni M, et al; Multicenter Study on Cerebral Hemorrhage in Italy (MUCH-Italy) Investigators. Antithrombotic medications and the etiology of intracerebral hemorrhage: MUCH-Italy. Neurology. 2014;82(6): 529-535.
50. Cucchiara B, Messe S, Sansing L, Kasner S, Lyden P; CHANT Investigators. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke. 2008;39(11):2993-2996.
51. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28(1):1-5.
52. Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage: incidence and time course. Stroke. 1996;27(10):1783-1787.
53. Biffi A, Greenberg SM. Cerebral amyloid angiopathy: a systematic review. J Clin Neurol. 2011; 7(1):1-9.
54. Steiner T, Diringer MN, Schneider D, et al. Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery. 2006;59(4):767-774.
55. Alonso A, Bengtson LG, MacLehose RF, Lutsey PL, Chen LY, Lakshminarayan K. Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. Stroke. 2014; 45(8):2286-2291.